ABSTRACT
The World Health Organization ranks Klebsiella pneumoniae as a priority antimicrobial-resistant (AMR) pathogen requiring urgent study. New strategies for diagnosis and treatment, particularly for those Klebsiella that are classified as carbapenem-resistant Enterobacteriaceae (CRE) need to recognize the increased prevalence of non-carbapenemase producing CRE (non-CP CRE). By integrating diverse Klebsiella genomes with known CRE phenotypes, we successfully identified a synchronized presence of CRE phenotype-related genes in plasmids and chromosomes in comparison to strains with carbapenem susceptible phenotypes. The data revealed a major contribution to CRE comes from the combined effect of chromosome and plasmid genes potentiated by modifications of outer membrane porins. Our computational workflow identified key gene contributors to the non-CP CRE phenotype, including those that lead to an increase of antibiotic expulsion by enhanced efflux pump activity and mobile elements that reduce antibiotic intake, such as IS1 and Tn3-like elements. These findings are consistent with a new model wherein a change to the balance in drug influx and efflux potentiates the ability of some beta-lactamases to enable survival in the presence of carbapenems. Analysis of the large numbers of documented CRE infections, as well as forensic analysis of a case study, showed that this potentiation can occur in short timeframes to deliver a non-CP CRE infection. Our results suggest that the multiple genes that function to build an AMR phenotype can be diagnosed, so that strains that will resist treatment with carbapenem treatment will be evident if a comprehensive genome-based diagnostic for CRE considers all of these sequence-accessible features.
SIGNIFICANCE Carbapenem-resistant Enterobacteriaceae (CRE) has emerged as an important challenge in health-care settings, with Klebsiella pneumoniae playing a major role in the global burden of CRE infections. Through systematic characterisation of the chromosome and plasmid genes of K. pneumoniae strains and their antimicrobial traits we identified new CRE mechanisms that are important for accurate diagnosis of carbapenem-resistant AMR. The development of comprehensive genomics-based diagnostics for CRE will need to consider the multiple gene signatures that impact together to deliver non-carbapenemase, carbapenem-resistant infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by research grants from the Australian National Health and Medical Research Council (APP1092262) National Natural Science Foundation of China (no.81971986) and the Health Department of Zhejiang Province of the Peoples Republic of China (no. 2011KYA106).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All of the investigation protocols in this study were approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (ethical number 2019-75). Informed consent was waived because this retrospective study focused on the bacterial isolates and had no impact on interventions to the patient.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The supplementary materials contain a list of sequence accession numbers. Code is available in https://github.com/LPerlaza/Assembly2Gene
